Antimicrobial resistance among invasive isolates of Streptococcus pneumoniae collected across Canada

Diagnostic Microbiology and Infectious Disease

Volumn 59, Issue 1, 2007, Pages 75-80

  Davidson, Ross J ^a   Melano, Roberto ^a   Forward, Kevin R ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Antibiotic resistance; Invasive S. pneumoniae; Surveillance

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN G; TELITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BLOOD CULTURE; CANADA; HUMAN; MICRODILUTION BROTH SUSCEPTIBILITY TESTING; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; STANDARD; STREPTOCOCCUS PNEUMONIAE;

BACTEREMIA; CANADA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; SENTINEL SURVEILLANCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 34548574688     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2007.03.024     Document Type: Article

References (36)

1. Andersson D.I., and Levin B.R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2 (1999) 489-493
2. Ball P. Therapy for pneumococcal infection at the millennium: doubts and certainties. Am. J. Med. 107 Suppl. 1A (1999) 77S-85S
3. Cirz R.T., Chin J.K., Andes D.R., de Crecy-Lagard V., Craig W.A., and Romesberg F.E. Inhibition of mutation and combating the evolution of antibiotic resistance. PLOS Biol. 3 (2005) 1-10
4. Clinical Laboratory Standards Institute. (2005). Performance Standards for Antimicrobial Susceptibility Testing: 15th Informational Supplement (2005), Clinical Laboratory Standards Institute, Wayne (PA)
5. Daneman N., McGeer A., Green K., Low D.E., and and the Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin. Infect. Dis. 43 (2006) 432-438
6. Davidson R., Cavalcanti R., Brunton J.L., et al. Resistance tolevofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346 (2002) 747-750
7. Davidson RJ, Chan CK, Doern G, Zhanel GG. Abstr. 13th Eur. Congress Clin. Microbiol. Infect. Dis, Abstr 1736, 2003.
8. de Azavedo J., Yeung R.H., bast D.J., Duncan C.L., Borgia S.B., and Low D.E. Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada. Antimicrob. Agents Chemother. 43 (1999) 2144-2147
9. Doern G.V., Pfaller M.A., Kugler K., Freeman J., and Jones R.N. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin. Infect. Dis. 27 (1998) 764-770
10. Doern G.V., Heilmann K.P., Huynh H.K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45 (2001) 1721-1729
11. Dowell S.F., Smith T., Leversedge K., and Snitzer J. Pneumonia treatment failure associated with highly resistant pneumococci. Clin. Infect. Dis. 29 (1999) 462-463
12. Feikin D.R., Schuchat A., Kolczak N., Berrett L., Harrison H., Lefkowitz L., et al. Mortality from invasive pneumococcal pneumonia in theera of antibiotic resistance, 1995-1997. Am. J. Public Health 90 (2000) 223-229
13. Felmingham D., and Gruneberg R.N. The Alexander project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J. Antimicrob. Chemother. 45 (2000) 191-203
14. File Jr T.M., and Tan J.S. Incidence, etiologic pathogens, and diagnostic testing of community-acquired pneumonia. Curr. Opin. Pulm. Med. 3 (1997) 89-97
15. Georges H., Leroy O., Vandenbussche C., et al. Epidemiological features and prognosis of severe community-acquired pneumococcal pneumonia. Intensive Care Med. 25 (1999) 198-206
16. Gleason P.P., Meehan T.P., Fine J.M., Galusha D.H., and Fine M.J. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch. Intern. Med. 159 (1999) 2562-2572
17. Heffelfinger J.D., Dowell S.F., Jorgensen J.H., et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch. Intern. Med. 160 (2000) 1399-1408
18. Lonks J.R., Garau J., Gomez L., Xercavins M., Ochoa D.E., Gareen F., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35 (2002) 556-564
19. Low D.E. Resistance and treatment implications: pneumococcus, Staphylococcus aureus and gram-negative rods. Infect. Dis. Clin. North Am. 3 (1998) 613-630
20. Low D.E. Quinolone resistance among pneumococci: therapeutic and diagnostic implications. Clin. Infect. Dis. 38 Suppl. 4 (2004) S357-S362
21. Low D.E., de Azavedo J., Weiss K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46 (2002) 1295-1301
22. Mandel L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell D., Dean N.C., et al. Infectious diseases society of America/American thoracic society consensus guidelines on the management of community acquired pneumonia in adults. Clin. Infect. Dis. 44 (2007) S27-S72
23. Martinez J.A., Horcajada J.P., Almeda M., et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin. Infect. Dis. 36 (2003) 389-395
24. Mufson M.A., and Stanek R.J. Bacteremic pneumococcal pneumonia in oneAmerican city: a 20-year longitudinal study, 1978-1997. Am. J. Med. 107 Suppl. (1999) 34S-43S
25. National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can. Commun. Dis. Rep. 28 (2000) 1-32
26. Pan X.S., Ambler J., Mehtar S., and Fisher L.M. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 40 (1996) 2321-2326
27. Powis J., McGeer A., Green K., Vanderkooi O., Weiss K., Zhanel G., et al. In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob. Agents Chemother. 48 (2004) 3305-3311
28. Reinert R.R., Reinert S., van der Linden M., Cil M.Y., Al-Lahham A., and Appelbaum P. Antimicrobial Susceptibility of Streptococcus pneumoniae in Eight European Countries from 2001 to 2003. Antimicrob. Agents Chemother. 49 (2005) 2903-2913
29. Sinner S.W., and Tunkel A.R. Antimicrobial agents in the treatment of bacterial meningitis. Infect. Dis. Clin. North Am. 18 (2004) 581-602
30. Stahl J.E., Barza M., DesJardin J., Martin R., and Eckman M.H. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch. Intern. Med. 159 (1999) 2576-2580
31. Sutcliffe J., Grebe T., Tait-Kamradt A., and Wondrack L. Detection of erythromycin-resistant determinants by PCR. Antimicrob. Agents Chemother. 40 (1996) 2562-2566
32. Turret G.S., Blum S., Fazal B.A., Justman J.E., and Telzak E.E. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high HIV seroprevalence. Clin. Infect. Dis. 29 (1999) 321-327
33. Waterer G.W., Wunderink R.G., and Jones C.B. Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest 118 (2000) 1839-1840
34. Waterer G.W., Somes G.W., and Wunderink R.G. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch. Intern. Med. 161 (2001) 1837-1842
35. Whitney C.G., Farley M.M., Hadler J., et al. Increasing prevalence ofmultidrug resistant Streptococcus pneumoniae in the United States. N. Engl. J. Med. 343 (2000) 1917-1924
36. Zhanel G.G., Palatnick L., Nichol K., Bellyou T., Low D.E., and Hoban D.J. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47 (2003) 1867-1874